Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transmembrane protein 86B (TMEM86B) is a membrane-bound hydrolase that serves as the major lysoplasmalogenase in mammals, catalyzing the cleavage of the vinyl ether bond in lysoplasmalogens to generate fatty aldehydes and glycerophosphocholine or glycerophosphoethanolamine. It is part of the YhhN protein family and is highly expressed in the liver, with lower expression in other tissues including duodenum and brain. TMEM86B plays a central role in ether lipid metabolism and the regulation of cellular plasmalogen levels, making it relevant to inherited and acquired diseases of lipid metabolism. Dysregulation may contribute to disorders like rhizomelic chondrodysplasia punctata and retinal degeneration conditions. No drugs currently target TMEM86B directly; however, its enzymatic activity and the resulting lipid species are important for understanding cellular lipid balance and related pathologies.
Not established in humans; inhibition or modulation may affect plasmalogen levels, which could be exploited therapeutically in disorders of lipid metabolism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transmembrane protein 86B (TMEM86B).